

# Chromosomal Microarray for Solid Tumors

MOL.TS.344.A  
v2.0.2025

Chromosomal microarray analysis (CMA) of solid tumors is addressed by this guideline.

**Procedures addressed**

The inclusion of any procedure code in this table does not imply that the code is under management or requires prior authorization. Refer to the specific Health Plan's procedure code list for management requirements.

| Procedures addressed by this guideline    | Procedure code(s) |
|-------------------------------------------|-------------------|
| Cytogenomic neoplasia microarray analysis | 81277             |

**Criteria**

Chromosomal microarray analysis (CMA) on solid tumor tissue is medically necessary in individuals who meet the following criteria:

- Member has been diagnosed with:
  - Cancer of the central nervous system, or
  - Soft tissue sarcoma, AND
- Rendering laboratory is a qualified provider of service per Health Plan policy.

**What are chromosome abnormalities in cancer?**

Chromosomal aberrations are known to contribute to tumorigenesis.<sup>1</sup>

**Chromosome Abnormalities in Cancer**

A chromosome abnormality is any difference in the structure, arrangement, or amount of genetic material packaged into the chromosomes. Chromosome abnormalities have been identified in many types of cancer, including leukemias, lymphomas, and solid tumors. Chromosome abnormalities can include deletions, duplications, balanced or unbalanced rearrangements, and gain or loss of whole or partial chromosomes. These abnormalities can play a key role in the development, diagnosis, and monitoring of

CMA Solid Tumors

cancer. The cytogenetics of a cancer can also change over time or in response to treatment. Therefore, chromosome analysis can be used to monitor disease progression and treatment response.

"[C]ancer is thought to be a consequence of genomic alteration accumulation, such as single-nucleotide variants (SNVs) and copy number variants (CNVs), and structural rearrangements, which encompass deletions, duplications, inversions, insertions, and translocations that could lead to novel fusion genes."<sup>2</sup>

Some chromosome abnormalities are characteristic of certain types of malignancy, and can be used to classify a type or subtype of cancer. For example, codeletion of 1p and 19q along with IDH1/2 mutations indicate oligodendroglioma.<sup>3</sup>

"The presence of specific chromosomal and genetic alterations exclusively observed in malignant cells helps in cancer diagnosis and prognosis, allowing also to quantify residual disease. Several different types and sizes of chromosomal abnormalities can be found in human cancers, being the products of these dysregulated genes and cellular pathways specific targets for new drugs."<sup>2</sup>

## Test information

Chromosome analysis of solid tumors can be done through traditional cytogenetic testing (karyotype), fluorescence in situ hybridization (FISH), or CMA. This guideline addresses only CMA on solid tumors.

### Chromosomal Microarray

CMA testing generally works by fluorescently tagging DNA from an individual's test sample with one color and combining it with a control sample tagged in a different color. The two samples are mixed and then added to the array chip, where they compete to hybridize with the DNA fragments on the chip. By comparing the test sample versus the control, computer analysis can determine where genetic material has been deleted or duplicated in the individual.

There are a growing number of CMA testing platforms, including non-chip based applications, which differ in approach and resolution. Clinical laboratories may not only differ in the arrays that they utilize but also in their reporting practices. Although testing guidelines do not endorse one CMA over another, it is typically advisable that coverage of an ordered CMA is better than that offered by a standard karyotype and that the minimum resolution of the CMA provided by the laboratory is adequate. The inclusion of analysis of subtelomeric regions and known microdeletion syndromes with CMA testing obviates the need for additional FISH analysis.

CMA testing offers advantages over conventional karyotyping with regard to resolution and yield. However, there are some limitations of CMA testing including:

- the inability to detect
  - balanced chromosomal rearrangements such as translocations or inversions
  - certain forms of polyploidy
  - sex chromosome aneuploidy dependent on the gender control used
  - low level mosaicism
  - some marker chromosomes
- the detection of CNVs of uncertain clinical significance
- the inability to differentiate free trisomies from unbalanced Robertsonian translocations.

## Guidelines and evidence

### American College of Medical Genetics and Genomics

The American College of Medical Genetics and Genomics (ACMG, 2019) provided technical standards and guidelines for interpretation and reporting of acquired copy number abnormalities and loss of heterozygosity in neoplastic disorders:<sup>4</sup>

- "Genomic testing of hematologic malignancies and solid tumors at the time of disease presentation provides information that is crucial for diagnosis and management. This evaluation may include G-banded chromosome analysis, fluorescence in situ hybridization (FISH) analysis, chromosomal microarray analysis (CMA), gene expression and fusion studies, targeted gene sequencing, as well as gene sequencing panels."
- "[A] unified approach for the clinical interpretation, classification, and reporting of all somatic variants will become a necessity."
- Tier 1 variants are those with a strong clinical significance, and several cytogenetic abnormalities in CNS cancers are classified as Tier 1. Additionally, select cytogenetic abnormalities are classified as Tier 1 in the following cancers:
  - Renal cell carcinoma
  - Pediatric embryonal cancers
  - Breast cancer
  - Bone cancer
  - Gastrointestinal stromal tumors
  - Mesothelioma
- "The laboratory must ensure that the clinical report accurately describes the findings and clearly communicates their clinical significance."

The American College of Medical Genetics and Genomics (ACMG, 2024) provided technical standards and guidelines for chromosome analysis in solid tumor-acquired chromosome abnormalities:<sup>5</sup>

- "Clinical cytogenomic studies of solid tumor samples are critical to the diagnosis, prognostication, and treatment selection for cancer patients."
- "Cytogenomic analysis of solid tumors is performed to detect and characterize chromosome alterations to support clinical care. This analysis may provide critical information for diagnosis, prognostication, and selection of therapy. Cytogenomic studies of tumor tissues may be accomplished by G-banded chromosome analysis, FISH, CMA, OGM [optical genome mapping], sequencing, or a combination of these methodologies."
- "CMA can provide valuable information to supplement that of G-banded chromosome and FISH analyses. ... Isolated tumor DNA hybridized to whole-genome copy number and/or single nucleotide polymorphism microarrays allows detection of loss, gain, and amplification of regions of DNA, which may not otherwise be detected by conventional cytogenetic methods."
- "Cytogenomic studies may reveal germline and/or secondary findings. It is recommended that laboratories refer to their policies and procedures to address these situations."

### National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN, 2024) guideline on soft tissue sarcoma stated:<sup>6</sup>

- "Morphologic diagnosis based on microscopic examination of histologic sections remains the gold standard for sarcoma diagnosis. However, several ancillary techniques are useful in support of morphologic diagnosis, including IHC [immunohistochemistry], classical cytogenetics, electron microscopy, and molecular genetic testing. Molecular genetic testing has emerged as an ancillary testing approach since many sarcoma types harbor characteristic gene aberrations, including single base pair substitutions, deletions and amplifications, and translocations. Molecular testing utilizes multiple techniques such as fluorescence in situ hybridization (FISH), or polymerase chain reaction (PCR)-based methods and next-generation sequencing (NGS)-based methods (including DNA and RNA sequencing)."

The National Comprehensive Cancer Network (NCCN, 2024) guideline on central nervous system (CNS) cancers stated:<sup>7</sup>

- "With the use of genetic and molecular testing, histologically similar CNS neoplasms can be differentiated more accurately in terms of prognosis and, in some instances, response to different therapies."
- "Molecular characterization of primary CNS tumors has substantially impacted clinical trial eligibility and risk stratification in the past 10 years, thereby evolving the standard of care towards an integrated tumor diagnosis in neuro-oncology".

- "Molecular/genetic characterization does not replace standard histologic assessment, but serves as a complementary approach to provide additional diagnostic and prognostic information that often enhances treatment selection."
- "Some diffusely infiltrative astrocytomas lack the histologic features of glioblastoma (necrosis and/or microvascular proliferation) but have the molecular hallmarks of glioblastoma, including one or more of the following: IDH wild-type; EGFR amplification; gain of chromosome 7 and loss of chromosome 10; and TERT promoter mutation. In such cases, the tumor can now be diagnosed as "Glioblastoma, IDH-wild-type, WHO grade 4". Because these tumors have similar clinical outcomes as typical grade 4 glioblastomas, they may be treated as such."
- "Recommendation: 1p/19q testing is an essential part of molecular diagnostics for oligodendroglioma."
- "Detection: The codeletion of 1p and 19q is detectable by array-based genomic copy number testing (preferable), or fluorescence in situ hybridization (FISH)."

## World Health Organization

The World Health Organization (WHO, 2021) classification of tumors of the central nervous system stated:<sup>3</sup>

- "Because of the growing importance of molecular information in CNS tumor classification, diagnoses and diagnostic reports need to combine different data types in a single "integrated" diagnosis. Such integrated diagnoses are implicit in the use of WHO CNS5... Thus, to display the full range of diagnostic information available the use of layered (or tiered) diagnostic reports is strongly encouraged... Such reports feature an integrated diagnosis at the top, followed by layers that display histological, molecular, and other key types of information."
- "In the updated fourth edition CNS classification from 2016, the common diffuse gliomas of adults were divided into 15 entities, largely because different grades were assigned to different entities (eg, Anaplastic oligodendroglioma was considered a different type from Oligodendroglioma) and because NOS designations were assigned to distinct entities (eg, Diffuse astrocytoma, NOS). WHO CNS5, on the other hand, includes only 3 types: Astrocytoma, IDH-mutant; Oligodendroglioma, IDH-mutant and 1p/19q-codeleted; and Glioblastoma, IDH-wildtype."
- "...[A]ll IDH-mutant diffuse astrocytic tumors are considered a single type (Astrocytoma, IDH-mutant) and are then graded as CNS WHO grade 2, 3, or 4. Moreover, grading is no longer entirely histological, since the presence of CDKN2A/B homozygous deletion results in a CNS WHO grade of 4, even in the absence of microvascular proliferation or necrosis."
- "For IDH-wildtype diffuse astrocytic (NB: diffuse and astrocytic) tumors in adults, a number of papers have shown that the presence of 1 or more of 3 genetic parameters (TERT promoter mutation, EGFR gene amplification, combined gain of entire chromosome 7 and loss of entire chromosome 10 [+7/-10]) appears sufficient

to assign the highest WHO grade. WHO CNS5 therefore incorporates these 3 genetic parameters as criteria for a diagnosis of Glioblastoma, IDH-wildtype. As a result, Glioblastoma, IDH-wildtype should be diagnosed in the setting of an IDH-wildtype diffuse and astrocytic glioma in adults if there is microvascular proliferation or necrosis or TERT promoter mutation or EGFR gene amplification or +7/-10 chromosome copy number changes."

- "Several molecular biomarkers are also associated with classification and grading of meningiomas, including SMARCE1 (clear cell subtype), BAP1 (rhabdoid and papillary subtypes), and KLF4/TRAF7 (secretory subtype) mutations, TERT promoter mutation and/or homozygous deletion of CDKN2A/B (CNS WHO grade 3), H3K27me3 loss of nuclear expression (potentially worse prognosis), and methylome profiling (prognostic subtyping)."

### Selected Relevant Publication

Ribeiro and colleagues stated in an expert-authored review (2019):<sup>2</sup>

- "Chromosome translocations, inversions, and insertions are frequently found in solid tumors..." however, "only few biomarkers have been approved for clinical practice that could change clinical decision making, helping in the therapeutic choices and patient management, showing the complexity of cancer and the lack of a strong bridge between the laboratory and clinicians."

---

### Note:

This benefit/harm statement only applies to those jurisdictions that do not have Medicare guidance. Based upon the guidelines and evidence provided in the clinical policy, following EviCore's criteria for chromosomal microarray for solid tumors will ensure that testing will be available to those members most likely to benefit from the information provided by the assay. For those not meeting criteria, it ensures alternate diagnostic/management strategies are considered. However, it is possible that some members who would benefit from the testing, but do not meet clinical criteria, will not receive an immediate approval for testing.

---

### References

1. Heim S, Mitelman F. Nonrandom chromosome abnormalities in cancer - an overview. In: Heim S, Mitelman F, eds. *Cancer Cytogenetics*. Hoboken, NJ: John Wiley and Sons, Inc.; 2009:25-44.
2. Ribeiro IP, Melo JB, Carreira IM. Cytogenetics and cytogenomics evaluation in cancer. *Int J Mol Sci* 2019;20(19). pii: E4711. doi: 10.3390/ijms20194711.
3. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro Oncol*. 2021 Aug 2;23(8):1231-1251.
4. Mikhail FM, Biegel JA, Cooley LD, et al. Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC). *Genet Med*. 2019;21(9):1903-1916.

5. Church AJ, Akkari Y, Deeb K, et al. Section E6.7-6.12 of the American College of Medical Genetics and Genomics (ACMG) Technical Laboratory Standards: Cytogenomic studies of acquired chromosomal abnormalities in solid tumors. *Genet Med*. 2024;101070
6. Von Mehren M, Kane J, Armstrong S, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2024 – April 26, 2024. Soft Tissue Sarcoma, available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/sarcoma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf). Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline®) for Soft Tissue Sarcoma V1.2024 – April 26, 2024. ©2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guideline® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guideline®, go online to NCCN.org
7. Nabors L, Portnow J, Baehring J, et al. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2024 – May 31, 2024. Central Nervous System Cancers, available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/cns.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf). Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline®) for Central Nervous System Cancers V1.2024 – May 31, 2024. ©2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guideline® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guideline®, go online to NCCN.o